Takeda Pharmaceutical (TAK) Other financing activities (2018 - 2026)

Takeda Pharmaceutical's Other financing activities history runs 9 years deep, the most recent figure standing at -$175.7 million for Q1 2026.

• On a quarterly basis, Other financing activities fell 140.92% year-over-year to -$175.7 million in Q1 2026; TTM through Mar 2026 was -$102.0 million, a 6.98% decrease from a year earlier, with the FY2026 full-year figure at -$86.4 million, up 20.91% from the prior year.
• Other financing activities slipped to -$175.7 million in Q1 2026 per TAK's latest filing, from $320.6 million in the prior quarter.
• Across five years, Other financing activities topped out at $429.4 million in Q1 2025 and bottomed at -$705.2 million in Q2 2024.
• The 5-year median for Other financing activities is $37.0 million (2022), against an average of -$28.0 million.
• Across the five-year window, Other financing activities plunged 722.15% in 2023 and jumped 642.07% in 2025, its largest moves.
• Year by year, Other financing activities stood at $234.6 million in 2022, then decreased by 21.76% to $183.6 million in 2023, then jumped by 33.53% to $245.1 million in 2024, then soared by 30.79% to $320.6 million in 2025, then sank by 154.81% to -$175.7 million in 2026.
• Per Business Quant, the three latest TAK Other financing activities figures stand at -$175.7 million (Q1 2026), $320.6 million (Q4 2025), and $350.4 million (Q3 2025).